Phreesia (FRA:19P) 3-Year RORE % : -83.35% (As of Apr. 2026)


FRA:19P Phreesia Inc FRA:19P
65 GF Score
Price €9.50
GF Value €23.45
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Phreesia 3-Year RORE %?

Phreesia FRA:19P +2.15% 65 3-Year RORE % is -83.35 as of Apr. 2026. GuruFocus rates FRA:19P with a GF Score™ of 65/100 and a GF Value™ of €23.45 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 606 Healthcare Providers & Services companies, Phreesia ranks worse than 88.94% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Phreesia's 3-Year RORE % for the quarter that ended in Apr. 2026 was -83.35%.

The industry rank for Phreesia's 3-Year RORE % or its related term are showing as below:

FRA:19P's 3-Year RORE % is ranked worse than
88.94% of 606 companies
in the Healthcare Providers & Services industry
Industry Median: 0.195 vs FRA:19P: -83.35

Phreesia  (FRA:19P) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Phreesia 3-Year RORE % Related Terms


Phreesia 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Phreesia's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Phreesia 3-Year RORE % Chart

Phreesia Annual Data
Trend Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24 Jan25 Jan26
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only -62.82 45.30 3.98 -35.15 -72.22

Phreesia Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -40.21 -48.42 -60.41 -72.22 -83.35

FRA:19P vs EVH, CTEV, MDRX: 3-Year RORE % Comparison

For the Health Information Services subindustry, Phreesia's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Phreesia 3-Year RORE % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Phreesia's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Phreesia's 3-Year RORE % falls into.


FRA:19P
65GF Score
Phreesia Inc FRA:19P
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Phreesia 3-Year RORE % Calculation

Phreesia's 3-Year RORE % for the quarter that ended in Apr. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( 0.129--2.004 )/( -2.559-0 )
=2.133/-2.559
=-83.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Apr. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -83.35 mean?
Phreesia (FRA:19P) has a 3-Year RORE % of -83.35 as of Apr. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Phreesia and its competitors. According to the industry distribution chart, Phreesia ranks #539 out of 606 companies in the Healthcare Providers & Services industry, placing it in the top 88.9%.
Is Phreesia's 3-Year RORE % too high?
Phreesia's current 3-Year RORE % is -83.35. Based on the distribution chart, Phreesia ranks #539 out of 606 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Phreesia has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Phreesia's 3-Year RORE % compare to EVH and CTEV?
According to the Healthcare Providers & Services industry distribution chart, Phreesia ranks #539 out of 606 companies for 3-Year RORE %. This places Phreesia in the lower half of its industry. The industry median 3-Year RORE % is 0.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Healthcare Providers & Services company?
The median 3-Year RORE % among Healthcare Providers & Services companies is 0.20, based on 606 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Phreesia and its competitors. For the Healthcare Providers & Services industry, the median 3-Year RORE % is 0.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Phreesia's current 3-Year RORE % is -83.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phreesia stock overvalued right now?
Based on GuruFocus' analysis, Phreesia (FRA:19P) is currently considered Possible Value Trap. The stock's GF Value™ is €23.45, compared to a current price of €9.50 — trading 59.5% below its estimated fair value. The current 3-Year RORE % is -83.35. Phreesia's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Phreesia (FRA:19P), the current 3-Year RORE % is -83.35 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Phreesia (FRA:19P) Overvalued in 2026?

Based on GuruFocus' analysis, Phreesia stock appears to be undervalued. The current stock price of €9.50 is trading 59.5% below its estimated GF Value™ of €23.45. GuruFocus considers Phreesia to be Possible Value Trap.

Key valuation signals for FRA:19P:

  • 3-Year RORE %: -83.35
  • GF Value™: €23.45 vs. price of €9.50 (59.5% below fair value)
  • GF Score™: 65/100 with 4 warning signs

No single metric tells the full story. See the FRA:19P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Phreesia Business Description

Other Exchanges PHR:USA
Address 1521 Concord Pike, Suite 301, PMB 221, Wilmington, DE, USA, 19803
Phreesia Inc is a provides an integrated software, payments, and engagement platform designed to address three foundational challenges in healthcare delivery: access to care, affordability of care, and patient health outcomes. Its platform is embedded directly into provider workflows and patient interactions, enabling healthcare organizations to activate patients, streamline administrative processes, and improve financial performance across the care continuum. The group serves a diverse group of healthcare organizations, including ambulatory practices, health systems, and hospitals, as well as life sciences companies, government entities, patient advocacy, public interest, and not-for-profit and other organizations.
65GF Score

Get the complete analysis for FRA:19P

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.50
Price
€23.45
GF Value